AI Article Synopsis
- The study analyzed data from 35 patients with cutaneous T-cell lymphomas (CTCLs) treated with alitretinoin over a 7-year period, focusing on demographics, treatment response, and side effects.
- About 37.2% of patients responded positively to the treatment, while 63% reported no side effects, with hypertriglyceridemia being the most common issue.
- The results suggest that alitretinoin could be a viable and low-cost treatment option for patients with less advanced CTCLs, as it demonstrated a good level of efficacy with minimal side effects.
Article Abstract
Introduction: In this survey, we analyzed data from patients suffering from the most common cutaneous T-cell lymphomas (CTCLs) subtypes mycosis fungoides (MF) and Sézary syndrome (SS), treated with the retinoid alitretinoin during a 7-year period at our outpatient department between 2015 and 2020.
Materials And Methods: We analyzed patient medical records including TNMB stage, side effects under therapy with alitretinoin, time to next treatment (TTNT), and previous photo documentation.
Results: A total of 35 patients with MF (n = 28) and SS (n = 7) were included in the study, of whom 69% were male and 31% were female. The mean age of onset was 56 ± 15 years in MF and 65.4 ± 10.8 years in SS with 51.4% having early stage (IA-IIA) and 48.6% having advanced stage (IIB-IVA) CTCL. Of these patients 37.2% responded to alitretinoin, 28.6% had a stable course, and 34.3% experienced progression. Alitretinoin was administered as a monotherapy (25.7%) or combined with five concomitant therapies (74.2%), most frequently with ECP (31.4%) and PUVA (11.4%). 63% did not report any side effects, most often hypertriglyceridemia (20%) was described.
Conclusion: Considering that nearly two thirds of the CTCL patients treated with alitretinoin showed a response or stable disease, together with a low number of side effects and low cost compared to bexarotene, alitretinoin may be a potential alternative in the treatment of less advanced CTCLs. This survey represents the largest number of recorded therapies with the retinoid alitretinoin in CTCLs in a European patient collective.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8525105 | PMC |
| http://dx.doi.org/10.1002/cam4.4237 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
How to reduce the adverse effects of weight stigma on the quality of life: a preferred reported items for systematic reviews and meta-analyses (PRISMA).
Front Psychol
December 2024
Département de psychologie, Université de Poitiers, Université François Rabelais de Tours, CNRS, Poitiers, UMR7295 Centre de recherches sur la cognition et l'apprentissage (CeRCA), Poitiers, France.
Introduction: Obesity, affecting 38% of adults globally, carries economic burdens and health risks like cardiovascular disease and diabetes. Weight-loss programs often face challenges due to stigma and poor body image, impacting individuals' quality of life. Research on interventions targeting weight stigma is lacking, emphasizing the need for comprehensive approaches addressing psychological and behavioral aspects for effective care.
View Article and Find Full Text PDFCase report: Complete response in TMB-H advanced uterine clear cell carcinoma: a case analysis of paclitaxel albumin-bound combined with PD-1/CTLA-4 bispecific antibody.
Front Immunol
December 2024
The Oncology Department of the First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China.
Background: Uterine clear cell carcinoma (UCCC) is a rare and aggressive subtype of endometrial cancer, often presenting at an advanced stage with poor prognosis. Treatment options for advanced or recurrent UCCC are currently limited, especially after platinum-based chemotherapy has failed.
Case Presentation: We present the case of a 49-year-old female diagnosed with stage IV uterine clear cell carcinoma.
Proton pump inhibitor effect on macrophage and neutrophil function: a systematic review.
Front Immunol
December 2024
College of Pharmacy, University of Houston, Houston, TX, United States.
Background: Proton pump inhibitors (PPIs) are one of the most used drugs worldwide. While generally considered safe, the usage of PPIs is associated with several adverse outcomes including acute infectious diseases. PPIs influence macrophage and neutrophil function although a systematic review has never been undertaken.
View Article and Find Full Text PDFAn immunoregulatory and metabolism-improving injectable hydrogel for cardiac repair after myocardial infarction.
Regen Biomater
November 2024
School of Materials Science and Engineering, Tianjin Key Laboratory of Composite and Functional Materials, Tianjin University, Tianjin 300350, China.
The hypoxia microenvironment post-myocardial infarction (MI) critically disturbs cellular metabolism and inflammation response, leading to scarce bioenergy supplying, prolonged inflammatory phase and high risk of cardiac fibrosis during cardiac restoration. Herein, an injectable hydrogel is prepared by Schiff base reaction between fructose-1,6-bisphosphate (FBP)-grafted carboxymethyl chitosan (CF) and oxidized dextran (OD), followed by loading fucoidan-coated baicalin (BA)-encapsulated zein nanoparticles (BFZ NPs), in which immunoregulatory and metabolism improving functions are integrally included. The grafted FBP serves to enhance glycolysis and provide more bioenergy for cardiomyocytes survival under hypoxia microenvironment, and elevating cellular antioxidant capacity pentose phosphate pathway.
View Article and Find Full Text PDFA general strategy towards activatable nanophotosensitizer for phototoxicity-free photodynamic therapy.
Theranostics
January 2025
Biomaterials Research Center, School of Biomedical Engineering, Southern Medical University 510515, Guangzhou, Guangdong Province, China.
Photodynamic therapy (PDT) has gained widespread attention in cancer treatment, but it still faces clinical problems such as skin phototoxicity. Activatable photosensitizers offer a promising approach to addressing this issue. However, several significant hurdles need to be overcome, including developing effective activation strategies and achieving the optimal balance between photodynamic effects and related side effects.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!